Effects of @entity36013 , a selective XXXX kinase inhibitor, on Burkitt's and @entity978 .

@entity1 @entity522 @entity36013 @entity706 @entity19 @entity5 @entity2109 @entity8187 @entity915 @entity16511 @entity31323 @entity978 @entity995
We studied the effects of @entity36013 , an @entity16511 kinase inhibitor, on @entity2109 ( @entity2109 ) and @entity978 ( @entity978 ) in @entity1 tissues and cell cultures and in a @entity19 xenograft model of @entity706 . @entity31323 levels were assessed by RT-PCR and immunohistochemistry. They were aberrantly expressed in @entity2109 and @entity978 cell lines, and in lymph nodes from @entity1 with @entity2109 and @entity978 . Next, activation of the @entity16511 promoter was detected by reporter gene assays. The promoter activity of @entity16511 kinase was high in @entity2109 cell lines and the @entity16511 promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site. @entity36013 -hQPA had antiproliferative effects in the @entity2109 and @entity978 cell lines studied; inhibited the phosphorylation of histone H3 and @entity995 proteins, and resulted in cells with > 4N DNA content. @entity36013 -hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of @entity8187 , followed by activation of @entity522 . This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/ @entity915 /yc(null) @entity19 implanted with the Ramos @entity1 @entity2109 cell line. @entity36013 had anti- @entity5 effects in this @entity19 xenograft model. There preclinical data suggest that the inhibition of @entity16511 kinase is a potentially useful therapeutic strategy in @entity2109 and @entity978 .
